Skip to main content

Liothyronine Sodium

Brand names: Cytomel, Liothyronine Sodium

l-Triiodothyronine Oral

At a glance

Medicare prescriptions, 2024
493,889
Medicare drug cost
$19.1M
Average cost per prescription
$38.71
Clinicians who prescribed it
16,784

Where it is prescribed

Loading map…

List the prescribers in any state, county, city or ZIP code →

What it is used for

CYTOMEL is an L-triiodothyronine (T3) indicated for: • Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism • Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer • Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

From the FDA-approved prescribing information (label dated May 2026). Full labels on DailyMed (opens in a new tab)

Boxed warning

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS • Thyroid hormones, including CYTOMEL, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. • In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. • Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.

Who prescribes it

All prescribers, by place, name or specialty →

Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.

Trend, 2019–2024

Medicare prescriptions rose 27% from 2019 to 2024.

Medicare Part D prescriptions per year, all prescribers
  • 2019598,524
  • 2020614,759
  • 2021625,355
  • 2022632,251
  • 2023674,010
  • 2024757,172

Biggest change by state since 2019

  • Oklahoma +75%
  • Kansas +73%
  • Alabama +62%
  • Utah +62%
  • Arkansas +58%
  • California (smallest change) +2%
  • Massachusetts (smallest change) +7%

From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.

What it looks like

Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.

Mylan Pharmaceuticals Inc.

StrengthLooks likeImprint
5 ugwhite round tablet, 6 mmKPI 115
25 ugwhite round tablet, 7 mm, scored to split in 2KPI 116
50 ugwhite round tablet, 8 mm, scored to split in 2KPI 117

Pfizer Laboratories Div Pfizer Inc

StrengthLooks likeImprint
5 ugwhite round tablet, 6 mmKPI 115
25 ugwhite round tablet, 7 mm, scored to split in 2KPI 116
50 ugwhite round tablet, 8 mm, scored to split in 2KPI 117

Preferred Pharmaceuticals Inc.

StrengthLooks likeImprint
5 ugwhite round tablet, 6 mm18

Teva Pharmaceuticals USA, Inc.

StrengthLooks likeImprint
5 ugwhite round tablet, 6 mmTV 1L
25 ugwhite round tablet, 7 mm, scored to split in 2TV 2L
50 ugwhite round tablet, 8 mm, scored to split in 2TV 3L

Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.

Industry payments about this drug

No industry payments to clinicians named this drug in 2025.

Recalls and shortages

Not on the FDA drug shortage list.

2 recalls since 2020

  • Dec 2023 · Sun Pharmaceutical Industries Inc · Class II
    Failed Impurities/Degradation Specifications
  • Oct 2023 · Sun Pharmaceutical Industries Inc · Class II
    Failed Impurities/Degradation Specifications.

See all recalls →

Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)

Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.